Posted by Michael Wonder on 03 Mar 2020
ICER to postpone assessment of gene therapy for beta thalassemia
3 March 2020 - Due to delay in regulatory submission, ICER will reinitiate assessment at a future date —
The Institute for Clinical and Economic Review (ICER) announced today that we plan to postpone our ongoing assessment of LentiGlobin (bluebird bio) for the treatment of beta thalassemia.
Once a clearer timeframe for the therapy’s FDA review is known, we will reinitiate this assessment and announce an updated timeframe, which will include a new date for our public meeting.
